Navigation Links
CRi Announces New Maestro(TM) EX In Vivo Imaging System with Improved Performance and an Affordable Price
Date:8/26/2008

WOBURN, Mass., Aug. 26 /PRNewswire/ -- Cambridge Research & Instrumentation, Inc. (CRi) announces the release of the Maestro(TM) EX In Vivo Imaging System. The new system incorporates CRi's state-of-the-art FLEX technology and becomes the entry-level instrument of choice for in vivo fluorescence imaging.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080826/NETU054 )

FLEX technology represents a significant advancement of CRi's unique solid-state tunable optics that for the first time enables both broad- and narrow-band spectral imaging at the click of a button. The user can select high optical throughput for reduced experiment times or increased spectral resolution for enhanced separation of similar fluorescent labels.

Accurate spectral detection is essential for quantitative signal unmixing. Patent-pending Maestro software tools complement the improved optical capabilities of the Maestro EX by ensuring accurate and automated characterization of fluorescent signals in spectrally complex samples. Dynamic Contrast Enhancement (DyCE(TM)) is available as an accessory. DyCE is a revolutionary all-optical anatomic imaging solution for mice that also helps eliminate signals from non-specific binding in much less time than conventional means-by as much as 90% less time.

"You will be able to detect and measure more markers in your mouse model and resolve even extremely closely spaced and overlapping emission signals." explains James Mansfield, Director of Multispectral Imaging Systems at CRi.

The Maestro EX enables more precise detection and quantitation of molecular probes in live animals and complements the automated high-throughput Maestro 2 imaging system, by providing comparable imaging performance in a design intended for lower-throughput manual operation.

By providing unprecedented accuracy, sensitivity, and flexibility, along with powerful and intuitive software, the Maestro EX solidifies CRi's reputation as the industry's leading provider of in vivo fluorescence imaging systems.

Cambridge Research & Instrumentation, Inc (CRi) is a Boston-based biomedical imaging company providing innovative optical imaging solutions for more than 20 years. CRi's multidisciplinary team is dedicated to providing comprehensive solutions that enable our customers to produce breakthroughs in research and medical care. CRi technology helps extract new disease-specific information from biological and clinical samples in the physiological, morphological, and biochemical context of intact tissues and organisms.

With over 80 patents pending and issued, CRi's award-winning innovations are being utilized around the world in a wide range of settings, ranging from academic researcher to pharmaceutical drug development to clinical medicine. CRi is headquartered in Woburn, Massachusetts, and operates a state-of-the-art manufacturing facility. We are able to rapidly design and manufacture system- level solutions for a variety of growing market applications.

Visit http://www.cri-inc.com/maestro-pr to find out more about the Maestro EX system.

For more information visit our website at http://www.cri-inc.com or contact:

Ross Nakatsuji

CRi Marketing/Sales Group Leader

35-B Cabot Road, Woburn, MA 01801 USA

(P) 1-781-935-9099, extension 177, (C) 1-781-405-4000,

(E) rnakatsuji@cri-inc.com


'/>"/>
SOURCE Cambridge Research & Instrumentation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... Calif. , Feb. 27, 2017  Titan ... therapeutics for the treatment of select chronic diseases ... today announced that the U.S. Food & Drug ... the ropinirole implant Investigational New Drug Application (IND) ... of the clinical study pending submission of the ...
(Date:2/28/2017)... and SAN FRANCISCO , February 27, 2017 ... Se D BioMedical ... of biotechnology assets   LOI contemplates capital infusion ... for building shareholder value   Amarantus names four new appointees ... Amarantus   SeD Biomedical Inc. (SeD ...
(Date:2/28/2017)... Feb. 27, 2017 Pulmonary drug delivery market ... from USD 36.10 billion in 2016, at a CAGR ... pulmonary route as an alternate route of drug delivery, ... increasing incidence of respiratory diseases such as COPD, asthma, ... growth during the forecast period. However, emerging markets and ...
Breaking Medicine Technology:
(Date:2/28/2017)... ... February 28, 2017 , ... ... healthcare automation intelligence company based in New York. , “Ensuring an intuitive, user-friendly ... workflow remains unaltered. Those two fundamental reasons are the reasons this acquisition is ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... overall body strength, which often leads to a host of health issues, including ... the American Geriatrics Society discovered that good overall muscle strength in older ...
(Date:2/27/2017)... ... ... The threat of nuclear warfare has long plagued this world. In July ... testing of nuclear weapons. Years later, when her co-workers began dying, Dot started searching ... Testing,” Clayton exposes the critical decisions made by agencies involved in the nuclear testing ...
(Date:2/27/2017)... ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines ... despite scientific studies, the Center for Disease Control ( CDC ) and Infectious Diseases ... Kenneth B. Liegner, M.D. has compiled into a single volume a compelling argument that ...
(Date:2/27/2017)... ... , ... New Jersey ranks among the top five states in the entire ... for advanced services is growing. , Project WE vs C is a focused ... their non-profit partners in their fight against cancer and in support of their shared ...
Breaking Medicine News(10 mins):